Jana Janockova
Overview
Explore the profile of Jana Janockova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gandini A, Goncalves A, Strocchi S, Albertini C, Janockova J, Tramarin A, et al.
ACS Chem Neurosci
. 2022 Nov;
13(23):3314-3329.
PMID: 36445009
Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well...
2.
Chrienova Z, Nepovimova E, Andrys R, Dolezal R, Janockova J, Muckova L, et al.
J Enzyme Inhib Med Chem
. 2022 Sep;
37(1):2605-2620.
PMID: 36131624
Twenty-four novel compounds bearing tetrahydroacridine and -propargyl moieties have been designed, synthesised, and evaluated for their anti-cholinesterase and anti-monoamine oxidase activities. Propargyltacrine (IC = 21 nM) was the most potent...
3.
Slovinska L, Harvanova D, Janockova J, Matejova J, Cibur P, Moravek M, et al.
Curr Issues Mol Biol
. 2022 Jun;
44(2):578-596.
PMID: 35723326
At present, there is no effective way to treat the consequences of spinal cord injury (SCI). SCI leads to the death of neural and glial cells and widespread neuroinflammation with...
4.
Harvanova D, Matejova J, Slovinska L, Lacko M, Gulova S, Fecskeova L, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269618
There is a lack of in vitro models able to plausibly represent the inflammation microenvironment of knee osteoarthritis (OA). We analyzed the molecules released from OA tissues (synovial membrane, cartilage,...
5.
Janockova J, Matejova J, Moravek M, Homolova L, Slovinska L, Nagyova A, et al.
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948379
Mesenchymal stem cells (MSCs) are of great interest to scientists due to their application in cell therapy of many diseases, as well as regenerative medicine and tissue engineering. Recently, there...
6.
Spakova T, Janockova J, Rosocha J
Int J Mol Sci
. 2021 Sep;
22(18).
PMID: 34575865
Autologous blood products, such as platelet-rich plasma (PRP), are gaining increasing interest in different fields of regenerative medicine. Although growth factors, the main components of PRP, are thought to stimulate...
7.
Janockova J, Slovinska L, Harvanova D, Spakova T, Rosocha J
J Biomed Sci
. 2021 May;
28(1):39.
PMID: 34030679
Mesenchymal stem cells (MSCs) have been demonstrated to have a great potential in the treatment of several diseases due to their differentiation and immunomodulatory capabilities and their ability to be...
8.
Mezeiova E, Hrabinova M, Hepnarova V, Jun D, Janockova J, Muckova L, et al.
Bioorg Med Chem Lett
. 2021 May;
43:128100.
PMID: 33984470
The search for novel and effective therapeutics for Alzheimer's disease (AD) is the main quest that remains to be resolved. The goal is to find a disease-modifying agent able to...
9.
Hudacova M, Hamulakova S, Konkolova E, Jendzelovsky R, Vargova J, Sevc J, et al.
Int J Mol Sci
. 2021 Apr;
22(8).
PMID: 33917200
A series of novel C4-C7-tethered biscoumarin derivatives (-) linked through piperazine moiety was designed, synthesized, and evaluated biological/therapeutic potential. Biscoumarin was found to be the most effective inhibitor of both...
10.
Gorecki L, Uliassi E, Bartolini M, Janockova J, Hrabinova M, Hepnarova V, et al.
ACS Chem Neurosci
. 2021 Apr;
12(9):1698-1715.
PMID: 33852284
Since 2002, no clinical candidate against Alzheimer's disease has reached the market; hence, an effective therapy is urgently needed. We followed the so-called "multitarget directed ligand" approach and designed 36...